12 Best Fundamentally Strong Penny Stocks to Buy Right Now

Page 5 of 10

6. Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Upside Potential as of September 19, 2025: 311.5%

According to the recent Form 13F filing with the SEC, Acadian Asset Management LLC expanded its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 25.9% in the first quarter. With the purchase of 451,044 shares, the investment manager now owns 2,195,191 shares of the company’s stock, representing an ownership stake of 2.03%.

Despite the company’s history of failures, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) appears to be on the right track for future success. Just recently, the company announced that new data from its Phase 2a trial of ATI-2138 for atopic dermatitis will be highlighted as a late-breaking abstract at the 2025 EADV Congress in Paris.

ATI-2138, a leading selective oral covalent inhibitor of ITK and JAK3, serves as a solution for moderate to severe atopic dermatitis. The session, delivered by Dr. Jessica Beaziz-Tordjman, covered the drug’s effectiveness in treating the condition.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a Pennsylvania-based clinical-stage biopharmaceutical company that develops novel drug candidates targeting immune-inflammatory diseases. Incorporated in 2012, the company operates through two segments: Therapeutics and Contract Research.

Page 5 of 10